Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;218(1):156-62.
doi: 10.1016/j.atherosclerosis.2011.04.005. Epub 2011 Apr 16.

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline

Amy M West  1 , Justin D Anderson, Craig H Meyer, Frederick H Epstein, Hongkun Wang, Klaus D Hagspiel, Stuart S Berr, Nancy L Harthun, Joseph M DiMaria, Jennifer R Hunter, John M Christopher, Joshua D Chew, Gabriel B Winberry, Christopher M Kramer
Affiliations
Randomized Controlled Trial

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline

Amy M West et al. Atherosclerosis. 2011 Sep.

Abstract

Background: Both statins and ezetimibe lower LDL-C, but ezetimibe's effect on atherosclerosis is controversial. We hypothesized that lowering LDL-C cholesterol by adding ezetimibe to statin therapy would regress atherosclerosis measured by magnetic resonance imaging (MRI) in the superficial femoral artery (SFA) in peripheral arterial disease (PAD).

Methods: Atherosclerotic plaque volume was measured in the proximal 15-20 cm of the SFA in 67 PAD patients (age 63 ± 10, ABI 0.69 ± 0.14) at baseline and annually × 2. Statin-naïve patients (n=34) were randomized to simvastatin 40 mg (S, n=16) or simvastatin 40 mg+ezetimibe 10mg (S+E, n=18). Patients already on statins but with LDL-C >80 mg/dl had open-label ezetimibe 10mg added (E, n=33). Repeated measures models estimated changes in plaque parameters over time and between-group differences.

Results: LDL-C was lower at year 1 in S+E (67 ± 7 mg/dl) than S (91 ± 8 mg/dl, p<0.05), but similar at year 2 (68 ± 10 mg/dl vs. 83 ± 11 mg/dl, respectively). Plaque volume did not change from baseline to year 2 in either S+E (11.5 ± 1.4-10.5 ± 1.3 cm(3), p=NS) or S (11.0 ± 1.5-10.5 ± 1.4 cm(3), p=NS). In E, plaque progressed from baseline to year 2 (10.0 ± 0.8-10.8 ± 0.9, p<0.01) despite a 22% decrease in LDL-C.

Conclusions: Statin initiation with or without ezetimibe in statin-naïve patients halts progression of peripheral atherosclerosis. When ezetimibe is added to patients previously on statins, peripheral atherosclerosis progressed. Thus, ezetimibe's effect on peripheral atherosclerosis may depend upon relative timing of statin therapy.

Trial registration: ClinicalTrials.gov NCT00587678.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTEREST

Drs. Epstein, Meyer, Hagspiel, and Kramer receive research support from Siemens Medical Solutions. All other authors have no declared conflicts of interest.

Figures

Figure 1
Figure 1
Patient flow diagram through the study.
Figure 2
Figure 2
Representative black blood turbo spin echo MRI of one 3mm slice of the superficial femoral artery (arrow) in a S+E patient (top) at baseline (A) and year two (B) demonstrating lack of change over time and an E patient (bottom) at baseline (C) and year two (D) demonstrating subtle plaque progression. Note the excellent match between imaging locations at the different time points.
Figure 3
Figure 3
Graph comparing change in plaque volume over time for each of the study groups (S= simvastatin only, S+E = simvastatin plus ezetimibe and E = open label ezetimibe added to ongoing statin use at baseline). *p<0.05 vs. baseline, †p<0.01 vs. baseline
See this image and copyright information in PMC

Comment in

References

    1. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–81. - PubMed
    1. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249–52. - PubMed
    1. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80. - PubMed
    1. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24. - PubMed
    1. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221–6. - PubMed

Publication types

MeSH terms

Associated data